SCHEMBL1052999

SCHEMBL1052999

CCOC(=O)C(=CN(C)C)C(=O)c1cc(I)c(F)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.39
KMT2A Q03164 6/20 0.39
MAPT P10636 5/20 0.39
NPSR1 Q6W5P4 4/20 0.39
LMNA P02545 3/20 0.39
CYP2C9 P11712 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
CYP11B1 P15538 5/20 0.34
CYP11B2 P19099 5/20 0.34
S1PR4 O95977 1/20 0.33
S1PR1 P21453 1/20 0.33
MAPK1 P28482 1/20 0.33
USP2 O75604 1/20 0.33
IDE P14735 1/20 0.33
TNNI3 P19429 1/20 0.33
TNNT2 P45379 1/20 0.33
TNNC1 P63316 1/20 0.33
GLO1 Q04760 1/20 0.33
DHODH Q02127 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3502382 1.00 MEN1 (0.39) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL12931067 0.90 MEN1 (0.37) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL6339982 0.89 KMT2A (0.42) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL17193050 0.89 KMT2A (0.42) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL6339979 0.89 KMT2A (0.42) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL12931114 0.88 MAPT (0.39) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL15085006 0.87 MAPT (0.42) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL14037238 0.86 MAPT (0.38) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL13225679 0.85 MEN1 (0.39) MEN1KMT2AMAPTNPSR1LMNA
SCHEMBL12961518 0.84 MEN1 (0.41) MEN1KMT2AMAPTNPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250091995-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC. (JP) 2025-03-20 US disclosed
EP-4299563-A2 COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND Japan Tobacco Inc. (JP) 2024-01-03 EP disclosed
EP-3281939-B1 COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2023-10-18 EP disclosed
US-20230190730-A1 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT JAPAN TOBACCO INC. (JP) 2023-06-22 US disclosed
US-20220235009-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC. (JP) 2022-07-28 US disclosed
US-20190185433-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC. (JP) 2019-06-20 US disclosed
EP-3281939-A1 METHOD OF PRODUCING STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND Japan Tobacco Inc. (JP) 2018-02-14 EP disclosed
US-20180029989-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC. (JP) 2018-02-01 US disclosed
US-20180029989-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC. (JP) 2018-02-01 US disclosed
CN-103965163-B A kind of carbostyril derivative containing pyrimidine ring and its production and use FUDAN UNIVERSITY (CN) 2016-01-20 CN disclosed
US-20100204271-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC. 2010-08-12 US disclosed
US-20090318702-A1 PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-12-24 US disclosed
US-7635704-B2 Stable crystal of 4-oxoquinoline compound JAPAN TOBACCO INC. (JP) 2009-12-22 US disclosed
US-7635704-B2 Stable crystal of 4-oxoquinoline compound JAPAN TOBACCO INC. (JP) 2009-12-22 US disclosed
US-7531554-B2 Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid JAPAN TOBACCO INC. (JP) 2009-05-12 US disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 US disclosed
US-7176220-B2 4-oxoquinoline compound and use thereof as pharmaceutical agent JAPAN TOBACCO INC. (JP) 2007-02-13 US disclosed
EP-1636190-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND Japan Tobacco, Inc. (JP) 2006-03-22 EP disclosed
US-20060030710-A1 Stable crystal of 4-oxoquinoline compound SHIONOGI & CO., LTD. (JP) 2006-02-09 US disclosed
WO-2005113508-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC. (JP) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204271-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND GRIN2D, KCNQ2, RCC1 MEN1 1461/4885KMT2A 30/4885MAPT 589/4885
US-20190185433-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND KCNQ2, RCC1, SFPQ MEN1 1289/4885KMT2A 36/4885MAPT 626/4885
US-20250091995-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND KCNQ2, KCNQ1, KCNQ5 MEN1 2841/4885KMT2A 48/4885MAPT 908/4885
US-20220235009-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND GRIN2D, KCNQ2, RCC1 MEN1 1461/4885KMT2A 30/4885MAPT 589/4885
US-20230190730-A1 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT IMPDH1, IMPDH2, DNTT MEN1 4618/4885KMT2A 95/4885MAPT 2829/4885
US-20090318702-A1 PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND CYP4X1, CYP3A4, CYP3A7 MEN1 3040/4885KMT2A 975/4885MAPT 4765/4885
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND IMPDH1, IMPDH2, CDK20 MEN1 2469/4885KMT2A 647/4885MAPT 4278/4885
US-20060030710-A1 Stable crystal of 4-oxoquinoline compound KCNQ2, RCC1, SFPQ MEN1 1289/4885KMT2A 36/4885MAPT 626/4885
US-20180029989-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND KCNQ2, RCC1, SFPQ MEN1 1289/4885KMT2A 36/4885MAPT 626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.